The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.
Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer.
['Visconti|Roberta|R|', 'Morra|Francesco|F|', 'Guggino|Gianluca|G|', 'Celetti|Angela|A|']
D000818:Animals D000970:Antineoplastic Agents D063646:Carcinogenesis D002289:Carcinoma, Non-Small-Cell Lung D003598:Cytoskeletal Proteins D055808:Drug Discovery D006801:Humans D007167:Immunotherapy D008168:Lung D008175:Lung Neoplasms D058990:Molecular Targeted Therapy D009361:Neoplasm Invasiveness
CCDC6 antineoplastic agents biomarkers lung neoplasms poly(ADP-ribose) polymerase inhibitors